ABSTRACT
Objective: To investigate the effects of chemotherapeutic drugs on CD44+CD24-/low cell subpopulation of triple-negative breast cancer. Methods: MDA-MB-231 cells were treated with paclitaxel, docetaxel, 5-fluorouracil, epirubicin, vinorelbine or gemcitabine at 0.2-, 1- and 5-fold of the drug peak plasma concentration (PPC) for 24, 48 and 72 h, respectively. The growth of MDA-MB-231 cells was detected by MTT assay. The percentage of CD44+CD24-/low cells was determined by flow cytometry (FCM) after treatment with different chemotherapeutic drugs at 1-fold of PPC for 48 h and after cell recovery. The change of percentage of CD44 +CD24-/low cell subpopulation in circulating blood from 10 patients with metastatic triple-negative breast cancer before and after chemotherapy was determined by FCM. Results: The proliferation ability of MDA-MB-231 cells was inhibited by the six chemotherapeutic drugs. The percentage of CD44+CD24-/low cells was not significantly increased especially in 5-fluorouracil-treated cell group(P<0.05) after treatment with different chemotherapeutic drugs at 1-fold of PPC. The percentage of CD44 +CD24-/low cells in circulating blood from 10 patients with metastatic triple-negative breast cancer was decreased after chemotherapy with 1-fold of PPC(P<0.05). Conclusion: The chemotherapeutic drugs of paclitaxel, docetaxel, 5-fluorouracil and epirubicin can reduce the percentage of CD44+CD24-/lowcell subpopulation, which in circulating blood can be decreased after chemotherapy in patients with metastatic triple-negative breast cancer. Copyright© 2011 by TUMOR.
ABSTRACT
<p><b>OBJECTIVE</b>To investigate the therapeutic effects of Aiyishu Injection (AYSI) on cancerous hydrothorax, quality of life (QOF), and cellular immune function of patients.</p><p><b>METHODS</b>Sixty late-stage cancer patients accompanied hydrothorax were randomly divided into the experimental group (EG) and the control group (CG), with thirty patients in each group. After thoracenteses being carried out in all patients for draining off hydropsy, to the patients in EG, AYSI was medicated, 50 ml by intrathoracic and another 50 ml by intravenous injection; while to the patients in CG chemotherapeutic agent or interleukin-2 (IL-2) was given. The same treatment, thoracentesis and medication, was repeated 3 days later. After 4 weeks, the volume of pleural effusion was measured with B-mode ultrasound to evaluate the therapeutic effects of AYSI. QOF, body weight and T-lymphocyte subsets were compared between the two groups before and after treatment.</p><p><b>RESULTS</b>The clinical efficacy was significantly higher in EG than that in CG (P < 0.01). Besides, QOF was significantly improved (P < 0.05) and levels of CD3+ , CD4+ , CD4+ /CD8+ in peripheral blood increased in EG after treatment, which were significantly different to those in CG (P < 0.01, P < 0.05).</p><p><b>CONCLUSION</b>AYSI has definite therapeutic effects on cancerous hydrothorax, it could improve QOF and cellular immune function in patients with cancer.</p>
Subject(s)
Animals , Humans , Antineoplastic Agents , Therapeutic Uses , Carcinoma, Non-Small-Cell Lung , Drug Therapy , Coleoptera , Chemistry , Hydrothorax , Drug Therapy , Injections , Lung Neoplasms , Drug Therapy , Materia Medica , Therapeutic Uses , T-Lymphocyte Subsets , Allergy and ImmunologyABSTRACT
Objective: To observe the role of rmh-TNF in enhancing the anti-angiogenesis effect of cisplatin on Lewis lung carcinoma in the mice.Methods: Lewis lung carcinoma model was established in C57BL/6 mice.Sixty model mice were randomly divided into 4 groups: control group,rmh-TNF group(1500000 U/kg),cisplatin group(6.15 mg/kg), and rmh-TNF plus cisplatin group.Twelve days after implantation of cancer cells,different drugs were injected intra- tumorallv for 3d.The expression of hypoxia inducible factor-1?(HIF-1?)gene in the tumor was identified by RT-PCR. Immunohistochemistry(IHC)image analysis was performed to determine the vascular endothelial growth factor(VEGF) and kinase domain region receptor(KDR)expression and the microvessel density(MVD).Expression of matrix metallo- proteinase-2(MMP-2)was detected by flow cytometry.Results: The MVD values in the control group,the rmh-TNF group,the DDP group and the combination group were(24.76?1.28),(18.95?1.22),(19.53?1.15),(10.43?1.05),respectively,with those of the rmh-TNF and DDP groups significantly lower than that of the control group and higher than that of the combination group(all P